Core Viewpoint - Eli Lilly is acquiring Ventyx Biosciences for $1.2 billion at a price of $14 per share, focusing on expanding its portfolio in autoimmune and metabolic diseases [1] Group 1: Acquisition Details - The acquisition is valued at $1.2 billion, with Eli Lilly paying $14 per share for Ventyx Biosciences [1] - The transaction is expected to be completed in the first half of this year [1] Group 2: Ventyx Biosciences' Pipeline - Ventyx is developing multiple therapies, including oral treatments for inflammatory bowel diseases such as Crohn's disease and ulcerative colitis [1] - The company is also working on drugs for immune-related diseases, cardiovascular diseases related to obesity, and neurodegenerative diseases [1] - One of the drugs in mid-stage trials targets cardiovascular diseases associated with obesity, which may complement Eli Lilly's metabolic and immune specialties [1]